Its therapeutic effects in ADHD are primarily mediated by inhibition of the presynaptic dopamine transporter, with a secondary effect on the noradrenaline transporter [12,13]. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.